Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 10/20 | 0.59 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.52 |
| ▸ | PRKAB2 | O43741 | 2/20 | 0.49 |
| ▸ | PRKAG1 | P54619 | 2/20 | 0.49 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.49 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.49 |
| ▸ | PRKAG3 | Q9UGI9 | 2/20 | 0.49 |
| ▸ | PRKAG2 | Q9UGJ0 | 2/20 | 0.49 |
| ▸ | PRKAB1 | Q9Y478 | 2/20 | 0.49 |
| ▸ | HTR4 | Q13639 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | MITF | O75030 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.40 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.40 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30589684 | 1.00 | NR4A2 (0.59) | NR4A2CREBBPPRKAB2PRKAG1PRKAA2 | |
| SCHEMBL25294847 | 1.00 | NR4A2 (0.59) | NR4A2CREBBPPRKAB2PRKAG1PRKAA2 | |
| SCHEMBL25300122 | 0.93 | NR4A2 (0.52) | NR4A2CREBBPPRKAB2PRKAG1PRKAA2 | |
| SCHEMBL25300121 | 0.93 | NR4A2 (0.52) | NR4A2CREBBPPRKAB2PRKAG1PRKAA2 | |
| SCHEMBL30589681 | 0.85 | NR4A2 (0.48) | NR4A2CREBBPPRKAB2PRKAG1PRKAA2 | |
| SCHEMBL25296635 | 0.85 | NR4A2 (0.48) | NR4A2CREBBPPRKAB2PRKAG1PRKAA2 | |
| SCHEMBL25260065 | 0.85 | NR4A2 (0.48) | NR4A2CREBBPPRKAB2PRKAG1PRKAA2 | |
| SCHEMBL25303322 | 0.85 | NR4A2 (0.59) | NR4A2CREBBPHTR4MEN1MITF | |
| SCHEMBL30589687 | 0.85 | NR4A2 (0.59) | NR4A2CREBBPHTR4MEN1MITF | |
| SCHEMBL25978407 | 0.83 | NR4A2 (0.60) | NR4A2CREBBPHTR4MEN1MITF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250060-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-08-10 | — | — | US | disclosed |
| WO-2023137034-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM DUE, INC. (US) | 2023-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250060-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | NR4A2 2070/4885CREBBP 87/4885PRKAB2 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.